Mary Lou Smith
YOU?
Author Swipe
View article: Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments
Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments Open
Background Overall side‐effect impact, the aggregated experience of multiple toxicities, can be captured with the single Functional Assessment of Cancer Therapy (FACT) item GP5 (“I am bothered by side effects of treatment”). The objective …
View article: Structural brain differences in school-aged children who are HIV-exposed uninfected
Structural brain differences in school-aged children who are HIV-exposed uninfected Open
Background Antiretroviral therapy (ART) has dramatically reduced perinatal HIV transmission, leading to a growing population of children who are HIV-exposed but uninfected (CHEU). While the neuroanatomic developmental impacts of in utero H…
View article: Intelligence and language outcomes in school-aged children who are HIV-exposed, uninfected: the role of sex, perinatal risk factors, and socioeconomic status
Intelligence and language outcomes in school-aged children who are HIV-exposed, uninfected: the role of sex, perinatal risk factors, and socioeconomic status Open
Background Children who are HIV-exposed uninfected (CHEU) are at increased risk for neurodevelopmental impairments. Most studies report on neurodevelopmental outcomes in the first 2 years of life, with limited data available for school-age…
View article: What defines response to vagus nerve stimulation in children with drug‐resistant epilepsy? A prospective cohort study from the <scp>CONNECTiVOS</scp> collaboration
What defines response to vagus nerve stimulation in children with drug‐resistant epilepsy? A prospective cohort study from the <span>CONNECTiVOS</span> collaboration Open
Objectives Responsiveness to vagus nerve stimulation (VNS) in children with drug‐resistant epilepsy (DRE) is often defined based on reduction in seizure frequency, typically at the 50% threshold, with limited consideration to the effects o…
View article: Diagnostic Challenges in the Neuropsychology of Epilepsy: Report of the <scp>ILAE</scp> Neuropsychology Task Force Diagnostic Methods Commission: 2021–2025
Diagnostic Challenges in the Neuropsychology of Epilepsy: Report of the <span>ILAE</span> Neuropsychology Task Force Diagnostic Methods Commission: 2021–2025 Open
Increasingly, it has been recognized that non‐seizure‐related factors influence how people with epilepsy perform on neuropsychological tests. Therefore, neuropsychologists need to recognize the constellation of factors that can contribute …
View article: Clinical implications of naming performance and seizure lateralization in bilingual children with epilepsy
Clinical implications of naming performance and seizure lateralization in bilingual children with epilepsy Open
Objective Naming difficulty is a common symptom of left (i.e., language dominant) hemisphere epilepsy. As such, in the presurgical evaluation for drug‐resistant epilepsy, which aims to localize the epileptogenic region, identification of a…
View article: Identifying the Financial Toxicity Experiences of Childhood Cancer Survivors Through Partnership With a Community Organization Serving Rural and Minoritized Families
Identifying the Financial Toxicity Experiences of Childhood Cancer Survivors Through Partnership With a Community Organization Serving Rural and Minoritized Families Open
Background Financial toxicity (FT) refers to cancer‐related economic distress and hardship, and disproportionately affects adolescent/young adult (AYA) survivors and minoritized groups. This study explored the FT experiences of AYA survivo…
View article: Consensus‐based recommendations for the diagnosis and treatment of anxiety and depression in children and adolescents with epilepsy: A report from the Psychiatric Pediatric Issues Task Force of the International League Against Epilepsy
Consensus‐based recommendations for the diagnosis and treatment of anxiety and depression in children and adolescents with epilepsy: A report from the Psychiatric Pediatric Issues Task Force of the International League Against Epilepsy Open
The Psychiatric Pediatric Issues Task Force of the International League Against Epilepsy (ILAE) aimed to develop recommendations for the diagnosis and treatment of anxiety and depression in children and adolescents with epilepsy. The Task …
View article: A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib Open
Aim: To evaluate the impact of palbociclib treatment on health-related quality of life (HRQoL) in patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (HR+/HER2- aBC) or metastatic breast…
View article: Advocate-BREAST: advocates and patients’ advice to enhance breast cancer care delivery, patient experience and patient centered research by 2025
Advocate-BREAST: advocates and patients’ advice to enhance breast cancer care delivery, patient experience and patient centered research by 2025 Open
Focused research and QI initiatives in these areas will improve the BC patient experience.
View article: Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years
Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years Open
Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥80 years (P80+). Identifying and addressing unmet needs are critical. Aims: Advocate-BREAST80+ compared the needs of P80+…
View article: Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women aged ≥ 80 years
Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women aged ≥ 80 years Open
Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥ 80 years (P80+). Identifying and addressing unmet needs are critical. Aims: Advocate-BREAST80+ compared the needs of P80…
View article: Add‐On Deep Brain Stimulation versus Continued Vagus Nerve Stimulation for Childhood Epilepsy (<scp>ADVANCE</scp>): A Partially Randomized Patient Preference Trial
Add‐On Deep Brain Stimulation versus Continued Vagus Nerve Stimulation for Childhood Epilepsy (<span>ADVANCE</span>): A Partially Randomized Patient Preference Trial Open
Outcomes following vagus nerve stimulation (VNS) improve over years after implantation in children with drug‐resistant epilepsy. The added value of deep brain stimulation (DBS) instead of continued VNS optimization is unknown. In a prospec…
View article: Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma Open
Importance There is substantial interest in capturing cancer treatment tolerability from the patient’s perspective using patient-reported outcomes (PROs). Objective To examine whether a PRO question, item 5 from the Functional Assessment o…
View article: Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework
Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework Open
Regulatory agencies are advancing the use of systematic approaches to collect patient experience data, including patient-reported outcomes (PROs), in cancer clinical trials to inform regulatory decision-making. Due in part to clinician und…
View article: 36 Naming in Monolingual and Bilingual Children with Epilepsy
36 Naming in Monolingual and Bilingual Children with Epilepsy Open
Objective: Word finding or “naming” difficulty is a symptom of multiple neurological disorders; therefore, naming assessment is an integral component of neuropsychological evaluation. Prior work has found weaker second-language naming in h…
View article: 59 Perinatal Risk Factors and Cognitive Outcomes in Children HIV-Exposed, Uninfected
59 Perinatal Risk Factors and Cognitive Outcomes in Children HIV-Exposed, Uninfected Open
Objective: Children who are HIV-exposed uninfected (CHEU) are at risk of neurodevelopmental impairments due to perinatal HIV and antiretroviral therapy exposure as well as additional health and psychosocial burdens. There is limited unders…
View article: Trajectories of parent well‐being in children with drug‐resistant epilepsy
Trajectories of parent well‐being in children with drug‐resistant epilepsy Open
Objective This longitudinal cohort study aimed to identify trajectories of parent well‐being over the first 2 years after their child's evaluation for candidacy for epilepsy surgery, and to identify the baseline clinical and demographic ch…
View article: Scoping review and expert‐based consensus recommendations for assessment and management of psychogenic non‐epileptic (functional) seizures (<scp>PNES</scp>) in children: A report from the Pediatric Psychiatric Issues Task Force of the International League Against Epilepsy
Scoping review and expert‐based consensus recommendations for assessment and management of psychogenic non‐epileptic (functional) seizures (<span>PNES</span>) in children: A report from the Pediatric Psychiatric Issues Task Force of the International League Against Epilepsy Open
Limited guidance exists regarding the assessment and management of psychogenic non‐epileptic seizures (PNES) in children. Our aim was to develop consensus‐based recommendations to fill this gap. The members of the International League Agai…
View article: Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Open
PURPOSE Despite defined grades of 1 to 5 for adverse events (AEs) on the basis of Common Terminology Criteria for Adverse Events criteria, mild (G1) and moderate (G2) AEs are often not reported in phase III trials. This under-reporting may…
View article: Advocate-BREAST: Advocates and Patients’ Advice to Enhance Breast Cancer Care Delivery, Patient Experience and Patient Centered Research by 2025
Advocate-BREAST: Advocates and Patients’ Advice to Enhance Breast Cancer Care Delivery, Patient Experience and Patient Centered Research by 2025 Open
Purpose: The aims of the Advocate-BREAST project are to study and improve the breast cancer (BC) patient experience through education and patient-centered research. Methods: In December 2021, an electronic REDCap survey was circulated to 6…
View article: NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023 Open
The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer…
View article: Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP Open
PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to …
View article: NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 Open
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy…
View article: Meeting Together in a Good Way: A Discussion on the Educational Mapping Activity of Indigenous Content in a Nurse Practitioner Program
Meeting Together in a Good Way: A Discussion on the Educational Mapping Activity of Indigenous Content in a Nurse Practitioner Program Open
A Primary Health Care Nurse Practitioner program carried out a unique curriculum mapping activity related to Indigenous content which resulted in the creation of a report entitled Maawanji'idiwag: Meeting Together in a Good Way. The activi…
View article: Supplementary Table 4 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Supplementary Table 4 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 Open
Supplementary Table 4 - Summary of SNPs with p<0.0001 in EA patients with Grade 2-4 NE in E5103.
View article: Data from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Data from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 Open
Purpose: Taxane-induced peripheral neuropathy (TIPN) is an important survivorship issue for many cancer patients. Currently, there are no clinically implemented biomarkers to predict which patients might be at increased risk for TIPN. We p…
View article: Supplementary Table 5 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Supplementary Table 5 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 Open
Supplementary Table 5 - Summary of SNPs with p<0.0001 in AA patients with Grade 2-4 NE in E5103.
View article: Supplementary Figures 1 - 2 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Supplementary Figures 1 - 2 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 Open
Supplementary Figure 1. Principal component analysis for patients in ECOG-5103 Supplementary Figure 2. Regional association (locuszoom) plots of rs3125923.